Activation of FXR pathway does not alter glial cell function

@inproceedings{Albrecht2017ActivationOF,
  title={Activation of FXR pathway does not alter glial cell function},
  author={Stefanie Albrecht and Ann-Katrin Fleck and Ina Kirchberg and Stephanie Hucke and Marie Liebmann and Luisa Klotz and Tanja Kuhlmann},
  booktitle={Journal of Neuroinflammation},
  year={2017}
}
BackgroundThe nuclear receptor farnesoid-X-receptor (FXR; NR1H4) is expressed not only in the liver, gut, kidney and adipose tissue but also in the immune cells. FXR has been shown to confer protection in several animal models of inflammation, including experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). FXR agonists are currently tested in clinical trials for treatment of human metabolic diseases. The beneficial effect of FXR agonists in EAE suggests… CONTINUE READING
BETA
2
Twitter Mentions

Similar Papers

Citations

Publications citing this paper.

Update on FXR Biology: Promising Therapeutic Target?

  • International journal of molecular sciences
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2015
VIEW 3 EXCERPTS